Fintel reports that on April 21, 2025, B of A Securities upgraded their outlook for United Therapeutics (NasdaqGS:UTHR) from ...

BofA upgraded United Therapeutics (UTHR) to Neutral from Underperform with a $314 price target Stay Ahead of the Market: Discover ...

As previously reported, BofA analyst Jason Gerberry upgraded United Therapeutics (UTHR) to Neutral from Underperform with an unchanged price ...

Wall Street expects a year-over-year increase in earnings on higher revenues when United Therapeutics (UTHR) reports results for the quarter ended March 2025. While this widely-known consensus outlook ...

A month has gone by since the last earnings report for United Therapeutics (UTHR). Shares have lost about 4.8% in that time frame, underperforming the S&P 500. Will the recent negative trend ...

Today, we are looking at therapeutics stocks, starting with United Therapeutics (NASDAQ:UTHR). Over the next few years, therapeutic companies, which develop a wide variety of treatments for ...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (UTHR) announced today that it will report its first quarter 2025 financial results before the ...

It is worth considering United Therapeutics (UTHR), which belongs to the Zacks Medical - Drugs industry. This drugmaker has an established record of topping earnings estimates, especially when ...

In this article, we are going to take a look at where United Therapeutics Corporation (NASDAQ:UTHR) stands against other most expensive stocks insiders are dumping in March. After being in the ...